Split (1)

train · 16k rows

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.

prompt stringlengths 1.92k 9.98k	response stringlengths 714 11k
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-939 Date of Submission: 2025-01-25 This report was submitted by a Patient from Walker-Palmer Medical Center concerning patient ANON-PX-2455. The subject is a 31-year-old other with a significant medical history including seasonal allergies, migraines, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 472mg, initiated on 2024-12-06 for Neuropathic pain and discontinued on 2025-01-07. On approximately 2024-12-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Somnolence. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Nice tree build seat. Citizen husband bed source here maybe. View walk sport.</data>	report_id: ADR-2025-939 report_date: '2025-01-25' patient_details: patient_id: ANON-PX-2455 gender: Other relevant_history: - seasonal allergies - migraines - anxiety age_at_reaction: 31 suspected_drugs: - drug_name: Gabapentin dosage: 472mg route_of_administration: Oral start_date: '2024-12-06' indication_for_use: Neuropathic pain drug_class: Anticonvulsant end_date: '2025-01-07' adverse_reactions: - symptom_name: Dizziness onset_date: '2024-12-10' severity: Mild outcome: Recovered intervention_required: false - symptom_name: Somnolence onset_date: '2024-12-10' severity: Life-threatening outcome: Fatal intervention_required: false causality_assessment: assessment_conclusion: Highly Probable dechallenge_rechallenge: Positive rechallenge naranjo_score: 9 reporting_facility: Walker-Palmer Medical Center reporter_type: Patient notes: Nice tree build seat. Citizen husband bed source here maybe. View walk sport.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-906 Date of Submission: 2024-10-08 This report was submitted by a Other Healthcare Professional from Kelly, Zamora and Thornton Medical Center concerning patient ANON-PX-2563. The subject is a 65-year-old female with a significant medical history including migraines, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Topical route at a dosage of 168mg, initiated on 2024-09-27 for Thromboembolism prevention with the course ongoing. On approximately 2024-10-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Somnolence, Stevens-Johnson syndrome, Maculopapular Rash, Diarrhea. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed huge and advised perhaps. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed tonight and advised I. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Our who ask success term.</data>	report_id: ADR-2024-906 report_date: '2024-10-08' patient_details: patient_id: ANON-PX-2563 gender: Female relevant_history: - migraines - anxiety age_at_reaction: 65 suspected_drugs: - drug_name: Warfarin dosage: 168mg route_of_administration: Topical start_date: '2024-09-27' indication_for_use: Thromboembolism prevention drug_class: Anticoagulant adverse_reactions: - symptom_name: Nausea onset_date: '2024-10-06' severity: Life-threatening outcome: Fatal intervention_required: false - symptom_name: Somnolence onset_date: '2024-10-06' severity: Moderate outcome: Recovering intervention_required: true intervention_details: Prescribed huge and advised perhaps. - symptom_name: Stevens-Johnson syndrome onset_date: '2024-10-06' severity: Severe outcome: Not Recovered intervention_required: true intervention_details: Prescribed tonight and advised I. - symptom_name: Maculopapular Rash onset_date: '2024-10-06' severity: Mild outcome: Fatal intervention_required: false - symptom_name: Diarrhea onset_date: '2024-10-06' severity: Life-threatening outcome: Not Recovered intervention_required: false causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Rechallenge not performed naranjo_score: 2 reporting_facility: Kelly, Zamora and Thornton Medical Center reporter_type: Other Healthcare Professional notes: Our who ask success term.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-592 Date of Submission: 2025-02-26 This report was submitted by a Other Healthcare Professional from Johnson PLC Medical Center concerning patient ANON-PX-5076. The subject is a 33-year-old female with a significant medical history including hypertension, asthma, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Sertraline administered via the Intravenous route at a dosage of 500mg, initiated on 2024-11-28 for Major depressive disorder with the course ongoing; Atorvastatin (Statin) administered via the Topical route at a dosage of 392mg, initiated on 2024-11-28 for Hypercholesterolemia with the course ongoing. On approximately 2024-12-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Headache, Angioedema. The Somnolence was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Shoulder consumer hand agreement that analysis poor skin. Argue world outside light nor court doctor. Level somebody house let foreign.</data>	report_id: ADR-2025-592 report_date: '2025-02-26' patient_details: patient_id: ANON-PX-5076 gender: Female relevant_history: - hypertension - asthma - coronary artery disease age_at_reaction: 33 suspected_drugs: - drug_name: Sertraline dosage: 500mg route_of_administration: Intravenous start_date: '2024-11-28' indication_for_use: Major depressive disorder - drug_name: Atorvastatin dosage: 392mg route_of_administration: Topical start_date: '2024-11-28' indication_for_use: Hypercholesterolemia drug_class: Statin adverse_reactions: - symptom_name: Somnolence onset_date: '2024-12-09' severity: Moderate outcome: Recovered intervention_required: false - symptom_name: Headache onset_date: '2024-12-09' severity: Severe outcome: Not Recovered intervention_required: false - symptom_name: Angioedema onset_date: '2024-12-09' severity: Life-threatening outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive rechallenge naranjo_score: 7 reporting_facility: Johnson PLC Medical Center reporter_type: Other Healthcare Professional notes: Shoulder consumer hand agreement that analysis poor skin. Argue world outside light nor court doctor. Level somebody house let foreign.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-471 Date of Submission: 2024-10-13 This report was submitted by a Other Healthcare Professional from Clark-Rose Medical Center concerning patient ANON-PX-2062. The subject is a 23-year-old other with a significant medical history including migraines, seasonal allergies, coronary artery disease, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Warfarin administered via the Oral route at a dosage of 373mg, initiated on 2024-07-29 for Thromboembolism prevention and discontinued on 2024-09-15. On approximately 2024-08-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Headache, Hepatotoxicity, Dizziness. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed off and advised best. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed foreign and advised onto. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed case and advised dark. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2024-471 report_date: '2024-10-13' patient_details: patient_id: ANON-PX-2062 gender: Other relevant_history: - migraines - seasonal allergies - coronary artery disease - type 2 diabetes age_at_reaction: 23 suspected_drugs: - drug_name: Warfarin dosage: 373mg route_of_administration: Oral start_date: '2024-07-29' indication_for_use: Thromboembolism prevention end_date: '2024-09-15' adverse_reactions: - symptom_name: Pruritus onset_date: '2024-08-28' severity: Life-threatening outcome: Recovering intervention_required: true intervention_details: Prescribed off and advised best. - symptom_name: Headache onset_date: '2024-08-28' severity: Mild outcome: Unknown intervention_required: false - symptom_name: Hepatotoxicity onset_date: '2024-08-28' severity: Mild outcome: Unknown intervention_required: true intervention_details: Prescribed foreign and advised onto. - symptom_name: Dizziness onset_date: '2024-08-28' severity: Mild outcome: Not Recovered intervention_required: true intervention_details: Prescribed case and advised dark. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge reporting_facility: Clark-Rose Medical Center reporter_type: Other Healthcare Professional
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-673 Date of Submission: 2025-04-08 This report was submitted by a Pharmacist from Scott-Wagner Medical Center concerning patient ANON-PX-7276. The subject is a 78-year-old male with a significant medical history including coronary artery disease, chronic kidney disease, asthma, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Intramuscular route at a dosage of 8mg, initiated on 2025-02-11 for Hypertension with the course ongoing. On approximately 2025-04-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Vomiting, Stevens-Johnson syndrome. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed identify and advised car. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed car and advised help. The current patient status regarding this symptom is 'Unknown'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2025-673 report_date: '2025-04-08' patient_details: patient_id: ANON-PX-7276 gender: Male relevant_history: - coronary artery disease - chronic kidney disease - asthma - type 2 diabetes age_at_reaction: 78 suspected_drugs: - drug_name: Lisinopril dosage: 8mg route_of_administration: Intramuscular start_date: '2025-02-11' indication_for_use: Hypertension drug_class: ACE inhibitor adverse_reactions: - symptom_name: Dizziness onset_date: '2025-04-02' severity: Mild outcome: Recovering intervention_required: true intervention_details: Prescribed identify and advised car. - symptom_name: Vomiting onset_date: '2025-04-02' severity: Mild outcome: Unknown intervention_required: false - symptom_name: Stevens-Johnson syndrome onset_date: '2025-04-02' severity: Mild outcome: Unknown intervention_required: true intervention_details: Prescribed car and advised help. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge naranjo_score: 8 reporting_facility: Scott-Wagner Medical Center reporter_type: Pharmacist
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-216 Date of Submission: 2024-12-05 This report was submitted by a Patient from Wright, Ortiz and Parker Medical Center concerning patient ANON-PX-3527. The subject is an adult female with a significant medical history including migraines, hypertension, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Lisinopril administered via the Intramuscular route at a dosage of 181mg, initiated on 2024-09-06 for Hypertension with the course ongoing; Ibuprofen (NSAID) administered via the Oral route at a dosage of 463mg, initiated on 2024-09-06 for Pain and inflammation with the course ongoing. On approximately 2024-10-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Diarrhea, Vomiting, Hepatotoxicity, Angioedema. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed end and advised concern. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2024-216 report_date: '2024-12-05' patient_details: patient_id: ANON-PX-3527 gender: Female relevant_history: - migraines - hypertension - anxiety suspected_drugs: - drug_name: Lisinopril dosage: 181mg route_of_administration: Intramuscular start_date: '2024-09-06' indication_for_use: Hypertension - drug_name: Ibuprofen dosage: 463mg route_of_administration: Oral start_date: '2024-09-06' indication_for_use: Pain and inflammation drug_class: NSAID adverse_reactions: - symptom_name: Stevens-Johnson syndrome onset_date: '2024-10-26' severity: Moderate outcome: Unknown intervention_required: false - symptom_name: Diarrhea onset_date: '2024-10-26' severity: Moderate outcome: Not Recovered intervention_required: false - symptom_name: Vomiting onset_date: '2024-10-26' severity: Severe outcome: Fatal intervention_required: true intervention_details: Prescribed end and advised concern. - symptom_name: Hepatotoxicity onset_date: '2024-10-26' severity: Life-threatening outcome: Recovering intervention_required: false - symptom_name: Angioedema onset_date: '2024-10-26' severity: Life-threatening outcome: Fatal intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge naranjo_score: 6 reporting_facility: Wright, Ortiz and Parker Medical Center reporter_type: Patient
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-167 Date of Submission: 2024-09-05 This report was submitted by a Other Healthcare Professional from Davis, Acosta and Jenkins Medical Center concerning patient ANON-PX-9235. The subject is an adult other with a significant medical history including coronary artery disease, anxiety, atrial fibrillation, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Lisinopril administered via the Intramuscular route at a dosage of 116mg, initiated on 2024-06-19 for Hypertension and discontinued on 2024-08-31; Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 498mg, initiated on 2024-06-19 for Hypercholesterolemia and discontinued on 2024-08-31. On approximately 2024-08-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Somnolence, Headache, Pruritus. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed small and advised leader. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed should and advised anyone. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: School increase my hope least ground. Take season article wish take around water.</data>	report_id: ADR-2024-167 report_date: '2024-09-05' patient_details: patient_id: ANON-PX-9235 gender: Other relevant_history: - coronary artery disease - anxiety - atrial fibrillation - asthma suspected_drugs: - drug_name: Lisinopril dosage: 116mg route_of_administration: Intramuscular start_date: '2024-06-19' indication_for_use: Hypertension end_date: '2024-08-31' - drug_name: Atorvastatin dosage: 498mg route_of_administration: Subcutaneous start_date: '2024-06-19' indication_for_use: Hypercholesterolemia drug_class: Statin end_date: '2024-08-31' adverse_reactions: - symptom_name: Diarrhea onset_date: '2024-08-27' severity: Moderate outcome: Recovered intervention_required: true intervention_details: Prescribed small and advised leader. - symptom_name: Somnolence onset_date: '2024-08-27' severity: Life-threatening outcome: Not Recovered intervention_required: true intervention_details: Prescribed should and advised anyone. - symptom_name: Headache onset_date: '2024-08-27' severity: Mild outcome: Fatal intervention_required: false - symptom_name: Pruritus onset_date: '2024-08-27' severity: Moderate outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge reporting_facility: Davis, Acosta and Jenkins Medical Center reporter_type: Other Healthcare Professional notes: School increase my hope least ground. Take season article wish take around water.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-434 Date of Submission: 2024-11-29 This report was submitted by a Physician from Meyer, Burnett and Preston Medical Center concerning patient ANON-PX-6340. The subject is a 31-year-old other with a significant medical history including atrial fibrillation, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intramuscular route at a dosage of 347mg, initiated on 2024-11-05 for Hypothyroidism and discontinued on 2024-11-22; Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 40mg, initiated on 2024-11-05 for Gastroesophageal reflux disease and discontinued on 2024-11-22. On approximately 2024-11-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Maculopapular Rash, Headache. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed or and advised city. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed central and advised meeting. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: College agency scientist hit story hold than. Class training lawyer prevent coach commercial admit relationship.</data>	report_id: ADR-2024-434 report_date: '2024-11-29' patient_details: patient_id: ANON-PX-6340 gender: Other relevant_history: - atrial fibrillation - seasonal allergies age_at_reaction: 31 suspected_drugs: - drug_name: Levothyroxine dosage: 347mg route_of_administration: Intramuscular start_date: '2024-11-05' indication_for_use: Hypothyroidism drug_class: Thyroid hormone end_date: '2024-11-22' - drug_name: Omeprazole dosage: 40mg route_of_administration: Intramuscular start_date: '2024-11-05' indication_for_use: Gastroesophageal reflux disease drug_class: Proton-pump inhibitor end_date: '2024-11-22' adverse_reactions: - symptom_name: Vomiting onset_date: '2024-11-17' severity: Severe outcome: Unknown intervention_required: true intervention_details: Prescribed or and advised city. - symptom_name: Maculopapular Rash onset_date: '2024-11-17' severity: Severe outcome: Recovering intervention_required: true - symptom_name: Headache onset_date: '2024-11-17' severity: Severe outcome: Recovering intervention_required: true intervention_details: Prescribed central and advised meeting. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive rechallenge naranjo_score: 5 reporting_facility: Meyer, Burnett and Preston Medical Center reporter_type: Physician notes: College agency scientist hit story hold than. Class training lawyer prevent coach commercial admit relationship.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-975 Date of Submission: 2025-03-23 This report was submitted by a Pharmacist from Cooke, Ramos and Roberson Medical Center concerning patient ANON-PX-6544. The subject is an adult female with a significant medical history including coronary artery disease, chronic kidney disease, asthma, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Oral route at a dosage of 93mg, initiated on 2025-01-05 for Hypercholesterolemia and discontinued on 2025-03-10; Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 92mg, initiated on 2025-01-05 for Hypothyroidism and discontinued on 2025-03-10. On approximately 2025-02-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Anaphylaxis, Maculopapular Rash, Vomiting. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Attack certain style leader question program see. Style very Democrat left everybody create remember.</data>	report_id: ADR-2025-975 report_date: '2025-03-23' patient_details: patient_id: ANON-PX-6544 gender: Female relevant_history: - coronary artery disease - chronic kidney disease - asthma - atrial fibrillation suspected_drugs: - drug_name: Atorvastatin dosage: 93mg route_of_administration: Oral start_date: '2025-01-05' indication_for_use: Hypercholesterolemia end_date: '2025-03-10' - drug_name: Levothyroxine dosage: 92mg route_of_administration: Intravenous start_date: '2025-01-05' indication_for_use: Hypothyroidism drug_class: Thyroid hormone end_date: '2025-03-10' adverse_reactions: - symptom_name: Stevens-Johnson syndrome onset_date: '2025-02-27' severity: Life-threatening outcome: Recovered intervention_required: false - symptom_name: Anaphylaxis onset_date: '2025-02-27' severity: Mild outcome: Fatal intervention_required: false - symptom_name: Maculopapular Rash onset_date: '2025-02-27' severity: Mild outcome: Not Recovered intervention_required: false - symptom_name: Vomiting onset_date: '2025-02-27' severity: Moderate outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Positive dechallenge naranjo_score: 4 reporting_facility: Cooke, Ramos and Roberson Medical Center reporter_type: Pharmacist notes: Attack certain style leader question program see. Style very Democrat left everybody create remember.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-837 Date of Submission: 2025-03-15 This report was submitted by a Patient from Gonzalez-Mckay Medical Center concerning patient ANON-PX-2719. The subject is a 49-year-old other with a significant medical history including hypertension, anxiety, osteoarthritis, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Subcutaneous route at a dosage of 407mg, initiated on 2025-02-11 for Type 2 diabetes and discontinued on 2025-03-04. On approximately 2025-03-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Somnolence. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed play and advised go. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Improve high study appear range inside least. Keep beat stand four significant everyone. Single talk prevent rise.</data>	report_id: ADR-2025-837 report_date: '2025-03-15' patient_details: patient_id: ANON-PX-2719 gender: Other relevant_history: - hypertension - anxiety - osteoarthritis - atrial fibrillation age_at_reaction: 49 suspected_drugs: - drug_name: Metformin dosage: 407mg route_of_administration: Subcutaneous start_date: '2025-02-11' indication_for_use: Type 2 diabetes drug_class: Biguanide end_date: '2025-03-04' adverse_reactions: - symptom_name: Stevens-Johnson syndrome onset_date: '2025-03-04' severity: Moderate outcome: Recovered intervention_required: true intervention_details: Prescribed play and advised go. - symptom_name: Somnolence onset_date: '2025-03-04' severity: Mild outcome: Recovering intervention_required: true causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Positive dechallenge naranjo_score: 1 reporting_facility: Gonzalez-Mckay Medical Center reporter_type: Patient notes: Improve high study appear range inside least. Keep beat stand four significant everyone. Single talk prevent rise.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-918 Date of Submission: 2024-10-22 This report was submitted by a Patient from Martin-Navarro Medical Center concerning patient ANON-PX-5159. The subject is an adult female with a significant medical history including asthma, atrial fibrillation, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Subcutaneous route at a dosage of 147mg, initiated on 2024-08-10 for Major depressive disorder and discontinued on 2024-10-20; Metformin (Biguanide) administered via the Oral route at a dosage of 462mg, initiated on 2024-08-10 for Type 2 diabetes and discontinued on 2024-10-20. On approximately 2024-10-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Diarrhea, Hepatotoxicity, Vomiting. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed somebody and advised real. The current patient status regarding this symptom is 'Recovered'. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed place and advised author. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed prove and advised site. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2024-918 report_date: '2024-10-22' patient_details: patient_id: ANON-PX-5159 gender: Female relevant_history: - asthma - atrial fibrillation - coronary artery disease suspected_drugs: - drug_name: Sertraline dosage: 147mg route_of_administration: Subcutaneous start_date: '2024-08-10' indication_for_use: Major depressive disorder drug_class: SSRI end_date: '2024-10-20' - drug_name: Metformin dosage: 462mg route_of_administration: Oral start_date: '2024-08-10' indication_for_use: Type 2 diabetes drug_class: Biguanide end_date: '2024-10-20' adverse_reactions: - symptom_name: Nausea onset_date: '2024-10-13' severity: Moderate outcome: Recovered intervention_required: true intervention_details: Prescribed somebody and advised real. - symptom_name: Diarrhea onset_date: '2024-10-13' severity: Severe outcome: Not Recovered intervention_required: true intervention_details: Prescribed place and advised author. - symptom_name: Hepatotoxicity onset_date: '2024-10-13' severity: Severe outcome: Not Recovered intervention_required: true intervention_details: Prescribed prove and advised site. - symptom_name: Vomiting onset_date: '2024-10-13' severity: Moderate outcome: Recovered intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive rechallenge reporting_facility: Martin-Navarro Medical Center reporter_type: Patient
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-294 Date of Submission: 2025-03-05 This report was submitted by a Patient from Bennett-Cohen Medical Center concerning patient ANON-PX-5790. The subject is a 73-year-old other with a significant medical history including type 2 diabetes, asthma, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intravenous route at a dosage of 431mg, initiated on 2024-12-15 for Gastroesophageal reflux disease and discontinued on 2025-03-03. On approximately 2025-02-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Dizziness, Headache, Vomiting, Diarrhea. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed per and advised cell. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed long and advised when. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2025-294 report_date: '2025-03-05' patient_details: patient_id: ANON-PX-5790 gender: Other relevant_history: - type 2 diabetes - asthma - atrial fibrillation age_at_reaction: 73 suspected_drugs: - drug_name: Omeprazole dosage: 431mg route_of_administration: Intravenous start_date: '2024-12-15' indication_for_use: Gastroesophageal reflux disease end_date: '2025-03-03' adverse_reactions: - symptom_name: Pruritus onset_date: '2025-02-15' severity: Life-threatening outcome: Not Recovered intervention_required: false - symptom_name: Dizziness onset_date: '2025-02-15' severity: Severe outcome: Not Recovered intervention_required: true intervention_details: Prescribed per and advised cell. - symptom_name: Headache onset_date: '2025-02-15' severity: Life-threatening outcome: Recovering intervention_required: false - symptom_name: Vomiting onset_date: '2025-02-15' severity: Severe outcome: Unknown intervention_required: false - symptom_name: Diarrhea onset_date: '2025-02-15' severity: Moderate outcome: Recovered intervention_required: true intervention_details: Prescribed long and advised when. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable reporting_facility: Bennett-Cohen Medical Center reporter_type: Patient
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-267 Date of Submission: 2024-11-28 This report was submitted by a Pharmacist from Strickland, Richards and Kelly Medical Center concerning patient ANON-PX-5049. The subject is a 64-year-old female with a significant medical history including migraines, anxiety, seasonal allergies, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Subcutaneous route at a dosage of 9mg, initiated on 2024-11-17 for Bacterial infection and discontinued on 2024-11-26; Lisinopril (ACE inhibitor) administered via the Topical route at a dosage of 232mg, initiated on 2024-11-17 for Hypertension and discontinued on 2024-11-26. On approximately 2024-11-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Anaphylaxis, Headache, Maculopapular Rash. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed player and advised traditional. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed eight and advised score. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: That film growth million sister. Short mention something. Rest education somebody cell majority law situation doctor. Finally reveal news seven so.</data>	report_id: ADR-2024-267 report_date: '2024-11-28' patient_details: patient_id: ANON-PX-5049 gender: Female relevant_history: - migraines - anxiety - seasonal allergies - hypertension age_at_reaction: 64 suspected_drugs: - drug_name: Amoxicillin dosage: 9mg route_of_administration: Subcutaneous start_date: '2024-11-17' indication_for_use: Bacterial infection drug_class: Penicillin antibiotic end_date: '2024-11-26' - drug_name: Lisinopril dosage: 232mg route_of_administration: Topical start_date: '2024-11-17' indication_for_use: Hypertension drug_class: ACE inhibitor end_date: '2024-11-26' adverse_reactions: - symptom_name: Angioedema onset_date: '2024-11-21' severity: Severe outcome: Not Recovered intervention_required: false - symptom_name: Anaphylaxis onset_date: '2024-11-21' severity: Moderate outcome: Recovered intervention_required: true intervention_details: Prescribed player and advised traditional. - symptom_name: Headache onset_date: '2024-11-21' severity: Severe outcome: Fatal intervention_required: false - symptom_name: Maculopapular Rash onset_date: '2024-11-21' severity: Moderate outcome: Fatal intervention_required: true intervention_details: Prescribed eight and advised score. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge naranjo_score: 6 reporting_facility: Strickland, Richards and Kelly Medical Center reporter_type: Pharmacist notes: That film growth million sister. Short mention something. Rest education somebody cell majority law situation doctor. Finally reveal news seven so.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-674 Date of Submission: 2025-05-07 This report was submitted by a Nurse from Rivera, West and Williams Medical Center concerning patient ANON-PX-7213. The subject is an adult female with a significant medical history including seasonal allergies, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Topical route at a dosage of 54mg, initiated on 2025-03-16 for Gastroesophageal reflux disease and discontinued on 2025-05-04. On approximately 2025-04-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Diarrhea. The Nausea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed action and advised after. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Finally take this add instead scene range. Each fast nature activity. Consider third despite audience house edge bill.</data>	report_id: ADR-2025-674 report_date: '2025-05-07' patient_details: patient_id: ANON-PX-7213 gender: Female relevant_history: - seasonal allergies - anxiety - osteoarthritis suspected_drugs: - drug_name: Omeprazole dosage: 54mg route_of_administration: Topical start_date: '2025-03-16' indication_for_use: Gastroesophageal reflux disease drug_class: Proton-pump inhibitor end_date: '2025-05-04' adverse_reactions: - symptom_name: Nausea onset_date: '2025-04-06' severity: Severe outcome: Not Recovered intervention_required: true intervention_details: Prescribed action and advised after. - symptom_name: Diarrhea onset_date: '2025-04-06' severity: Moderate outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge reporting_facility: Rivera, West and Williams Medical Center reporter_type: Nurse notes: Finally take this add instead scene range. Each fast nature activity. Consider third despite audience house edge bill.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-376 Date of Submission: 2025-01-10 This report was submitted by a Physician from Davis-Tate Medical Center concerning patient ANON-PX-5173. The subject is a 32-year-old male with a significant medical history including type 2 diabetes, asthma, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Oral route at a dosage of 442mg, initiated on 2024-12-08 for Neuropathic pain and discontinued on 2025-01-07. On approximately 2024-12-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Headache, Vomiting, Diarrhea. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Go family leader final. Charge enjoy every teach well news region. Low toward throughout actually. Government reason chair rate lay size.</data>	report_id: ADR-2025-376 report_date: '2025-01-10' patient_details: patient_id: ANON-PX-5173 gender: Male relevant_history: - type 2 diabetes - asthma - migraines age_at_reaction: 32 suspected_drugs: - drug_name: Gabapentin dosage: 442mg route_of_administration: Oral start_date: '2024-12-08' indication_for_use: Neuropathic pain drug_class: Anticonvulsant end_date: '2025-01-07' adverse_reactions: - symptom_name: Hepatotoxicity onset_date: '2024-12-16' severity: Severe outcome: Recovered intervention_required: true - symptom_name: Headache onset_date: '2024-12-16' severity: Life-threatening outcome: Recovered intervention_required: false - symptom_name: Vomiting onset_date: '2024-12-16' severity: Moderate outcome: Not Recovered intervention_required: false - symptom_name: Diarrhea onset_date: '2024-12-16' severity: Severe outcome: Recovered intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable naranjo_score: 8 reporting_facility: Davis-Tate Medical Center reporter_type: Physician notes: Go family leader final. Charge enjoy every teach well news region. Low toward throughout actually. Government reason chair rate lay size.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-424 Date of Submission: 2024-09-23 This report was submitted by a Other Healthcare Professional from Golden, Soto and Hernandez Medical Center concerning patient ANON-PX-6069. The subject is an adult female with a significant medical history including type 2 diabetes, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Sertraline administered via the Intravenous route at a dosage of 91mg, initiated on 2024-07-01 for Major depressive disorder and discontinued on 2024-09-16. On approximately 2024-07-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Diarrhea, Anaphylaxis, Stevens-Johnson syndrome. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed citizen and advised probably. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2024-424 report_date: '2024-09-23' patient_details: patient_id: ANON-PX-6069 gender: Female relevant_history: - type 2 diabetes - anxiety suspected_drugs: - drug_name: Sertraline dosage: 91mg route_of_administration: Intravenous start_date: '2024-07-01' indication_for_use: Major depressive disorder end_date: '2024-09-16' adverse_reactions: - symptom_name: Maculopapular Rash onset_date: '2024-07-24' severity: Severe outcome: Not Recovered intervention_required: false - symptom_name: Diarrhea onset_date: '2024-07-24' severity: Severe outcome: Recovering intervention_required: false - symptom_name: Anaphylaxis onset_date: '2024-07-24' severity: Mild outcome: Fatal intervention_required: false - symptom_name: Stevens-Johnson syndrome onset_date: '2024-07-24' severity: Severe outcome: Recovered intervention_required: true intervention_details: Prescribed citizen and advised probably. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive dechallenge reporting_facility: Golden, Soto and Hernandez Medical Center reporter_type: Other Healthcare Professional
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-460 Date of Submission: 2024-11-15 This report was submitted by a Nurse from Mccann and Sons Medical Center concerning patient ANON-PX-1444. The subject is a 89-year-old male with a significant medical history including coronary artery disease, atrial fibrillation, migraines, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Subcutaneous route at a dosage of 484mg, initiated on 2024-09-27 for Major depressive disorder and discontinued on 2024-10-28; Metformin administered via the Intravenous route at a dosage of 387mg, initiated on 2024-09-27 for Type 2 diabetes and discontinued on 2024-10-28. On approximately 2024-10-20, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Maculopapular Rash, Anaphylaxis, Nausea, Stevens-Johnson syndrome. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed reality and advised identify. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed single and advised skin. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2024-460 report_date: '2024-11-15' patient_details: patient_id: ANON-PX-1444 gender: Male relevant_history: - coronary artery disease - atrial fibrillation - migraines - seasonal allergies age_at_reaction: 89 suspected_drugs: - drug_name: Sertraline dosage: 484mg route_of_administration: Subcutaneous start_date: '2024-09-27' indication_for_use: Major depressive disorder drug_class: SSRI end_date: '2024-10-28' - drug_name: Metformin dosage: 387mg route_of_administration: Intravenous start_date: '2024-09-27' indication_for_use: Type 2 diabetes end_date: '2024-10-28' adverse_reactions: - symptom_name: Dizziness onset_date: '2024-10-20' severity: Mild outcome: Recovering intervention_required: true intervention_details: Prescribed reality and advised identify. - symptom_name: Maculopapular Rash onset_date: '2024-10-20' severity: Mild outcome: Unknown intervention_required: false - symptom_name: Anaphylaxis onset_date: '2024-10-20' severity: Severe outcome: Recovered intervention_required: false - symptom_name: Nausea onset_date: '2024-10-20' severity: Mild outcome: Unknown intervention_required: false - symptom_name: Stevens-Johnson syndrome onset_date: '2024-10-20' severity: Mild outcome: Recovered intervention_required: true intervention_details: Prescribed single and advised skin. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable naranjo_score: 7 reporting_facility: Mccann and Sons Medical Center reporter_type: Nurse
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-147 Date of Submission: 2025-08-08 This report was submitted by a Pharmacist from Sanders, Wilkins and Meyer Medical Center concerning patient ANON-PX-5303. The subject is an adult female with a significant medical history including seasonal allergies, atrial fibrillation, type 2 diabetes, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Subcutaneous route at a dosage of 212mg, initiated on 2025-05-23 for Pain and inflammation and discontinued on 2025-08-03; Levothyroxine (Thyroid hormone) administered via the Intramuscular route at a dosage of 314mg, initiated on 2025-05-23 for Hypothyroidism and discontinued on 2025-08-03. On approximately 2025-07-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Stevens-Johnson syndrome, Dizziness, Pruritus, Somnolence. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Space positive office trouble mouth what administration day. Everybody trial see area Mrs just theory defense. Whether hard structure sell within.</data>	report_id: ADR-2025-147 report_date: '2025-08-08' patient_details: patient_id: ANON-PX-5303 gender: Female relevant_history: - seasonal allergies - atrial fibrillation - type 2 diabetes - anxiety suspected_drugs: - drug_name: Ibuprofen dosage: 212mg route_of_administration: Subcutaneous start_date: '2025-05-23' indication_for_use: Pain and inflammation drug_class: NSAID end_date: '2025-08-03' - drug_name: Levothyroxine dosage: 314mg route_of_administration: Intramuscular start_date: '2025-05-23' indication_for_use: Hypothyroidism drug_class: Thyroid hormone end_date: '2025-08-03' adverse_reactions: - symptom_name: Diarrhea onset_date: '2025-07-25' severity: Severe outcome: Not Recovered intervention_required: false - symptom_name: Stevens-Johnson syndrome onset_date: '2025-07-25' severity: Severe outcome: Fatal intervention_required: false - symptom_name: Dizziness onset_date: '2025-07-25' severity: Mild outcome: Unknown intervention_required: true - symptom_name: Pruritus onset_date: '2025-07-25' severity: Moderate outcome: Fatal intervention_required: false - symptom_name: Somnolence onset_date: '2025-07-25' severity: Moderate outcome: Not Recovered intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge naranjo_score: 7 reporting_facility: Sanders, Wilkins and Meyer Medical Center reporter_type: Pharmacist notes: Space positive office trouble mouth what administration day. Everybody trial see area Mrs just theory defense. Whether hard structure sell within.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-882 Date of Submission: 2025-01-20 This report was submitted by a Physician from Patel, Garner and Arnold Medical Center concerning patient ANON-PX-2702. The subject is a 36-year-old other with a significant medical history including chronic kidney disease, seasonal allergies, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Subcutaneous route at a dosage of 223mg, initiated on 2024-12-21 for Pain and inflammation and discontinued on 2025-01-09. On approximately 2024-12-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Angioedema. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Keep whatever story professor strategy sort. Still go common off house form.</data>	report_id: ADR-2025-882 report_date: '2025-01-20' patient_details: patient_id: ANON-PX-2702 gender: Other relevant_history: - chronic kidney disease - seasonal allergies - type 2 diabetes age_at_reaction: 36 suspected_drugs: - drug_name: Ibuprofen dosage: 223mg route_of_administration: Subcutaneous start_date: '2024-12-21' indication_for_use: Pain and inflammation drug_class: NSAID end_date: '2025-01-09' adverse_reactions: - symptom_name: Stevens-Johnson syndrome onset_date: '2024-12-27' severity: Moderate outcome: Fatal intervention_required: false - symptom_name: Angioedema onset_date: '2024-12-27' severity: Moderate outcome: Fatal intervention_required: true causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Positive rechallenge naranjo_score: 1 reporting_facility: Patel, Garner and Arnold Medical Center reporter_type: Physician notes: Keep whatever story professor strategy sort. Still go common off house form.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-493 Date of Submission: 2025-01-26 This report was submitted by a Other Healthcare Professional from Ross, Spencer and Ramirez Medical Center concerning patient ANON-PX-2218. The subject is an adult female with a significant medical history including osteoarthritis, atrial fibrillation, coronary artery disease, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 448mg, initiated on 2025-01-06 for Gastroesophageal reflux disease with the course ongoing; Lisinopril (ACE inhibitor) administered via the Intravenous route at a dosage of 96mg, initiated on 2025-01-06 for Hypertension with the course ongoing. On approximately 2025-01-14, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed course and advised as. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Hospital rather four yard father sort.</data>	report_id: ADR-2025-493 report_date: '2025-01-26' patient_details: patient_id: ANON-PX-2218 gender: Female relevant_history: - osteoarthritis - atrial fibrillation - coronary artery disease - asthma suspected_drugs: - drug_name: Omeprazole dosage: 448mg route_of_administration: Intravenous start_date: '2025-01-06' indication_for_use: Gastroesophageal reflux disease drug_class: Proton-pump inhibitor - drug_name: Lisinopril dosage: 96mg route_of_administration: Intravenous start_date: '2025-01-06' indication_for_use: Hypertension drug_class: ACE inhibitor adverse_reactions: - symptom_name: Dizziness onset_date: '2025-01-14' severity: Life-threatening outcome: Unknown intervention_required: false - symptom_name: Headache onset_date: '2025-01-14' severity: Mild outcome: Recovering intervention_required: true intervention_details: Prescribed course and advised as. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable reporting_facility: Ross, Spencer and Ramirez Medical Center reporter_type: Other Healthcare Professional notes: Hospital rather four yard father sort.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-653 Date of Submission: 2025-04-01 This report was submitted by a Physician from Clark Ltd Medical Center concerning patient ANON-PX-8126. The subject is a 82-year-old female with a significant medical history including chronic kidney disease, asthma, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intravenous route at a dosage of 107mg, initiated on 2025-03-14 for Gastroesophageal reflux disease with the course ongoing. On approximately 2025-03-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Maculopapular Rash, Stevens-Johnson syndrome, Angioedema. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Herself coach huge research. Them kind investment ground.</data>	report_id: ADR-2025-653 report_date: '2025-04-01' patient_details: patient_id: ANON-PX-8126 gender: Female relevant_history: - chronic kidney disease - asthma - migraines age_at_reaction: 82 suspected_drugs: - drug_name: Omeprazole dosage: 107mg route_of_administration: Intravenous start_date: '2025-03-14' indication_for_use: Gastroesophageal reflux disease adverse_reactions: - symptom_name: Dizziness onset_date: '2025-03-28' severity: Moderate outcome: Unknown intervention_required: false - symptom_name: Maculopapular Rash onset_date: '2025-03-28' severity: Moderate outcome: Recovered intervention_required: false - symptom_name: Stevens-Johnson syndrome onset_date: '2025-03-28' severity: Life-threatening outcome: Recovering intervention_required: false - symptom_name: Angioedema onset_date: '2025-03-28' severity: Life-threatening outcome: Fatal intervention_required: true causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Rechallenge not performed naranjo_score: 2 reporting_facility: Clark Ltd Medical Center reporter_type: Physician notes: Herself coach huge research. Them kind investment ground.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-132 Date of Submission: 2025-06-26 This report was submitted by a Physician from Fisher, Hardy and Shelton Medical Center concerning patient ANON-PX-6284. The subject is an adult other with a significant medical history including seasonal allergies, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Subcutaneous route at a dosage of 469mg, initiated on 2025-06-16 for Hypertension and discontinued on 2025-06-25; Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 298mg, initiated on 2025-06-16 for Hypothyroidism and discontinued on 2025-06-25. On approximately 2025-06-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Nausea, Diarrhea. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed impact and advised but. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Democrat society candidate difficult quality. Someone event since peace may agree.</data>	report_id: ADR-2025-132 report_date: '2025-06-26' patient_details: patient_id: ANON-PX-6284 gender: Other relevant_history: - seasonal allergies - coronary artery disease suspected_drugs: - drug_name: Lisinopril dosage: 469mg route_of_administration: Subcutaneous start_date: '2025-06-16' indication_for_use: Hypertension drug_class: ACE inhibitor end_date: '2025-06-25' - drug_name: Levothyroxine dosage: 298mg route_of_administration: Oral start_date: '2025-06-16' indication_for_use: Hypothyroidism drug_class: Thyroid hormone end_date: '2025-06-25' adverse_reactions: - symptom_name: Pruritus onset_date: '2025-06-23' severity: Mild outcome: Fatal intervention_required: true intervention_details: Prescribed impact and advised but. - symptom_name: Nausea onset_date: '2025-06-23' severity: Moderate outcome: Recovering intervention_required: false - symptom_name: Diarrhea onset_date: '2025-06-23' severity: Life-threatening outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable naranjo_score: 7 reporting_facility: Fisher, Hardy and Shelton Medical Center reporter_type: Physician notes: Democrat society candidate difficult quality. Someone event since peace may agree.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-600 Date of Submission: 2024-09-21 This report was submitted by a Nurse from Vance-Williams Medical Center concerning patient ANON-PX-5533. The subject is an adult male with a significant medical history including seasonal allergies, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Topical route at a dosage of 48mg, initiated on 2024-07-08 for Hypercholesterolemia and discontinued on 2024-09-05. On approximately 2024-08-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Maculopapular Rash, Somnolence, Headache. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed a and advised dog. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed within and advised present. The current patient status regarding this symptom is 'Unknown'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Stand though answer beautiful sign wear behind. Together office though small. Heart dinner wrong government race gun.</data>	report_id: ADR-2024-600 report_date: '2024-09-21' patient_details: patient_id: ANON-PX-5533 gender: Male relevant_history: - seasonal allergies - coronary artery disease suspected_drugs: - drug_name: Atorvastatin dosage: 48mg route_of_administration: Topical start_date: '2024-07-08' indication_for_use: Hypercholesterolemia drug_class: Statin end_date: '2024-09-05' adverse_reactions: - symptom_name: Hepatotoxicity onset_date: '2024-08-18' severity: Moderate outcome: Recovered intervention_required: true - symptom_name: Maculopapular Rash onset_date: '2024-08-18' severity: Mild outcome: Not Recovered intervention_required: true - symptom_name: Somnolence onset_date: '2024-08-18' severity: Life-threatening outcome: Recovering intervention_required: true intervention_details: Prescribed a and advised dog. - symptom_name: Headache onset_date: '2024-08-18' severity: Mild outcome: Unknown intervention_required: true intervention_details: Prescribed within and advised present. causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Positive dechallenge naranjo_score: 1 reporting_facility: Vance-Williams Medical Center reporter_type: Nurse notes: Stand though answer beautiful sign wear behind. Together office though small. Heart dinner wrong government race gun.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-680 Date of Submission: 2025-01-09 This report was submitted by a Other Healthcare Professional from Moore, Kim and Harmon Medical Center concerning patient ANON-PX-3358. The subject is a 85-year-old other with a significant medical history including hypertension, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Topical route at a dosage of 307mg, initiated on 2024-12-10 for Major depressive disorder and discontinued on 2025-01-05. On approximately 2024-12-20, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Dizziness. The Vomiting was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed none and advised PM. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Military star western after. Soon enter effort life color door suggest. Present read whole card military. Resource however skill.</data>	report_id: ADR-2025-680 report_date: '2025-01-09' patient_details: patient_id: ANON-PX-3358 gender: Other relevant_history: - hypertension - migraines age_at_reaction: 85 suspected_drugs: - drug_name: Sertraline dosage: 307mg route_of_administration: Topical start_date: '2024-12-10' indication_for_use: Major depressive disorder drug_class: SSRI end_date: '2025-01-05' adverse_reactions: - symptom_name: Vomiting onset_date: '2024-12-20' severity: Mild outcome: Recovering intervention_required: true intervention_details: Prescribed none and advised PM. - symptom_name: Dizziness onset_date: '2024-12-20' severity: Mild outcome: Not Recovered intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable naranjo_score: 8 reporting_facility: Moore, Kim and Harmon Medical Center reporter_type: Other Healthcare Professional notes: Military star western after. Soon enter effort life color door suggest. Present read whole card military. Resource however skill.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-669 Date of Submission: 2024-09-08 This report was submitted by a Nurse from Thomas, Campbell and Williams Medical Center concerning patient ANON-PX-1274. The subject is a 35-year-old female with a significant medical history including chronic kidney disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Sertraline administered via the Intramuscular route at a dosage of 30mg, initiated on 2024-07-07 for Major depressive disorder with the course ongoing. On approximately 2024-08-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Vomiting, Maculopapular Rash, Diarrhea, Angioedema. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed yet and advised resource. The current patient status regarding this symptom is 'Unknown'. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed less and advised could. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Give Mr five listen. Although here paper even.</data>	report_id: ADR-2024-669 report_date: '2024-09-08' patient_details: patient_id: ANON-PX-1274 gender: Female relevant_history: - chronic kidney disease - atrial fibrillation age_at_reaction: 35 suspected_drugs: - drug_name: Sertraline dosage: 30mg route_of_administration: Intramuscular start_date: '2024-07-07' indication_for_use: Major depressive disorder adverse_reactions: - symptom_name: Nausea onset_date: '2024-08-13' severity: Mild outcome: Unknown intervention_required: true intervention_details: Prescribed yet and advised resource. - symptom_name: Vomiting onset_date: '2024-08-13' severity: Severe outcome: Not Recovered intervention_required: false - symptom_name: Maculopapular Rash onset_date: '2024-08-13' severity: Severe outcome: Recovering intervention_required: false - symptom_name: Diarrhea onset_date: '2024-08-13' severity: Moderate outcome: Recovered intervention_required: true intervention_details: Prescribed less and advised could. - symptom_name: Angioedema onset_date: '2024-08-13' severity: Severe outcome: Not Recovered intervention_required: true causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive rechallenge reporting_facility: Thomas, Campbell and Williams Medical Center reporter_type: Nurse notes: Give Mr five listen. Although here paper even.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-407 Date of Submission: 2024-12-05 This report was submitted by a Pharmacist from Vasquez and Sons Medical Center concerning patient ANON-PX-8833. The subject is an adult other with a significant medical history including coronary artery disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intravenous route at a dosage of 441mg, initiated on 2024-10-20 for Gastroesophageal reflux disease and discontinued on 2024-11-29. On approximately 2024-11-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache, Stevens-Johnson syndrome. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed heavy and advised box. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed weight and advised after. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Exactly serve space upon center machine. Network citizen pretty discuss how across ready picture. Play near why consider common natural staff.</data>	report_id: ADR-2024-407 report_date: '2024-12-05' patient_details: patient_id: ANON-PX-8833 gender: Other relevant_history: - coronary artery disease - migraines suspected_drugs: - drug_name: Omeprazole dosage: 441mg route_of_administration: Intravenous start_date: '2024-10-20' indication_for_use: Gastroesophageal reflux disease end_date: '2024-11-29' adverse_reactions: - symptom_name: Dizziness onset_date: '2024-11-16' severity: Life-threatening outcome: Recovered intervention_required: true intervention_details: Prescribed heavy and advised box. - symptom_name: Headache onset_date: '2024-11-16' severity: Mild outcome: Fatal intervention_required: false - symptom_name: Stevens-Johnson syndrome onset_date: '2024-11-16' severity: Mild outcome: Fatal intervention_required: true intervention_details: Prescribed weight and advised after. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable naranjo_score: 5 reporting_facility: Vasquez and Sons Medical Center reporter_type: Pharmacist notes: Exactly serve space upon center machine. Network citizen pretty discuss how across ready picture. Play near why consider common natural staff.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-547 Date of Submission: 2024-08-28 This report was submitted by a Pharmacist from Hill-English Medical Center concerning patient ANON-PX-8200. The subject is a 43-year-old male with a significant medical history including asthma, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 187mg, initiated on 2024-07-30 for Gastroesophageal reflux disease with the course ongoing; Metformin (Biguanide) administered via the Oral route at a dosage of 39mg, initiated on 2024-07-30 for Type 2 diabetes with the course ongoing. On approximately 2024-08-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Headache, Stevens-Johnson syndrome, Dizziness, Somnolence. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed likely and advised culture. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Address owner main less. Collection she the protect. Maybe know behavior pass. Option ready democratic strong senior process.</data>	report_id: ADR-2024-547 report_date: '2024-08-28' patient_details: patient_id: ANON-PX-8200 gender: Male relevant_history: - asthma - atrial fibrillation age_at_reaction: 43 suspected_drugs: - drug_name: Omeprazole dosage: 187mg route_of_administration: Intramuscular start_date: '2024-07-30' indication_for_use: Gastroesophageal reflux disease drug_class: Proton-pump inhibitor - drug_name: Metformin dosage: 39mg route_of_administration: Oral start_date: '2024-07-30' indication_for_use: Type 2 diabetes drug_class: Biguanide adverse_reactions: - symptom_name: Hepatotoxicity onset_date: '2024-08-17' severity: Life-threatening outcome: Recovered intervention_required: true - symptom_name: Headache onset_date: '2024-08-17' severity: Moderate outcome: Fatal intervention_required: true - symptom_name: Stevens-Johnson syndrome onset_date: '2024-08-17' severity: Moderate outcome: Not Recovered intervention_required: false - symptom_name: Dizziness onset_date: '2024-08-17' severity: Moderate outcome: Recovering intervention_required: true intervention_details: Prescribed likely and advised culture. - symptom_name: Somnolence onset_date: '2024-08-17' severity: Severe outcome: Not Recovered intervention_required: false causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Positive dechallenge naranjo_score: 1 reporting_facility: Hill-English Medical Center reporter_type: Pharmacist notes: Address owner main less. Collection she the protect. Maybe know behavior pass. Option ready democratic strong senior process.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-262 Date of Submission: 2025-02-09 This report was submitted by a Patient from Johnson-Vazquez Medical Center concerning patient ANON-PX-3091. The subject is a 58-year-old other with a significant medical history including anxiety, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Intravenous route at a dosage of 38mg, initiated on 2025-01-19 for Hypercholesterolemia with the course ongoing. On approximately 2025-01-31, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Headache. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Talk level husband trial. Choose student traditional call million. Major series long reflect.</data>	report_id: ADR-2025-262 report_date: '2025-02-09' patient_details: patient_id: ANON-PX-3091 gender: Other relevant_history: - anxiety - migraines age_at_reaction: 58 suspected_drugs: - drug_name: Atorvastatin dosage: 38mg route_of_administration: Intravenous start_date: '2025-01-19' indication_for_use: Hypercholesterolemia drug_class: Statin adverse_reactions: - symptom_name: Vomiting onset_date: '2025-01-31' severity: Severe outcome: Recovering intervention_required: false - symptom_name: Headache onset_date: '2025-01-31' severity: Moderate outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive dechallenge reporting_facility: Johnson-Vazquez Medical Center reporter_type: Patient notes: Talk level husband trial. Choose student traditional call million. Major series long reflect.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-885 Date of Submission: 2025-07-14 This report was submitted by a Patient from Brown-Grant Medical Center concerning patient ANON-PX-2170. The subject is a 78-year-old male with a significant medical history including chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Amoxicillin administered via the Oral route at a dosage of 74mg, initiated on 2025-06-12 for Bacterial infection and discontinued on 2025-06-26. On approximately 2025-06-16, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Dizziness. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed loss and advised step. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Structure represent room produce phone. Movie then figure pick guy she. Billion arrive teacher center sign step citizen.</data>	report_id: ADR-2025-885 report_date: '2025-07-14' patient_details: patient_id: ANON-PX-2170 gender: Male relevant_history: - chronic kidney disease - anxiety age_at_reaction: 78 suspected_drugs: - drug_name: Amoxicillin dosage: 74mg route_of_administration: Oral start_date: '2025-06-12' indication_for_use: Bacterial infection end_date: '2025-06-26' adverse_reactions: - symptom_name: Headache onset_date: '2025-06-16' severity: Severe outcome: Unknown intervention_required: true intervention_details: Prescribed loss and advised step. - symptom_name: Dizziness onset_date: '2025-06-16' severity: Severe outcome: Not Recovered intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Not applicable naranjo_score: 5 reporting_facility: Brown-Grant Medical Center reporter_type: Patient notes: Structure represent room produce phone. Movie then figure pick guy she. Billion arrive teacher center sign step citizen.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-332 Date of Submission: 2025-06-12 This report was submitted by a Pharmacist from Jones-Summers Medical Center concerning patient ANON-PX-8381. The subject is a 65-year-old other with a significant medical history including coronary artery disease, atrial fibrillation, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intramuscular route at a dosage of 489mg, initiated on 2025-05-14 for Gastroesophageal reflux disease with the course ongoing. On approximately 2025-05-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Pruritus, Dizziness, Maculopapular Rash, Hepatotoxicity. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed federal and advised speech. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Door peace local approach space know. Fast glass within democratic describe exactly. Fire what need great.</data>	report_id: ADR-2025-332 report_date: '2025-06-12' patient_details: patient_id: ANON-PX-8381 gender: Other relevant_history: - coronary artery disease - atrial fibrillation - osteoarthritis age_at_reaction: 65 suspected_drugs: - drug_name: Omeprazole dosage: 489mg route_of_administration: Intramuscular start_date: '2025-05-14' indication_for_use: Gastroesophageal reflux disease adverse_reactions: - symptom_name: Diarrhea onset_date: '2025-05-24' severity: Life-threatening outcome: Unknown intervention_required: true - symptom_name: Pruritus onset_date: '2025-05-24' severity: Life-threatening outcome: Fatal intervention_required: true intervention_details: Prescribed federal and advised speech. - symptom_name: Dizziness onset_date: '2025-05-24' severity: Mild outcome: Recovered intervention_required: true - symptom_name: Maculopapular Rash onset_date: '2025-05-24' severity: Moderate outcome: Not Recovered intervention_required: false - symptom_name: Hepatotoxicity onset_date: '2025-05-24' severity: Life-threatening outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Not applicable naranjo_score: 3 reporting_facility: Jones-Summers Medical Center reporter_type: Pharmacist notes: Door peace local approach space know. Fast glass within democratic describe exactly. Fire what need great.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-654 Date of Submission: 2024-09-05 This report was submitted by a Nurse from Le and Sons Medical Center concerning patient ANON-PX-2453. The subject is a 69-year-old other with a significant medical history including hypertension, type 2 diabetes, anxiety, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 151mg, initiated on 2024-06-09 for Neuropathic pain and discontinued on 2024-08-12. On approximately 2024-07-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Nausea, Stevens-Johnson syndrome, Headache, Hepatotoxicity. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed sing and advised boy. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed box and advised inside. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed bar and advised again. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Public manage prevent important claim. Dream people road Mr machine PM continue. Available too start worry.</data>	report_id: ADR-2024-654 report_date: '2024-09-05' patient_details: patient_id: ANON-PX-2453 gender: Other relevant_history: - hypertension - type 2 diabetes - anxiety - migraines age_at_reaction: 69 suspected_drugs: - drug_name: Gabapentin dosage: 151mg route_of_administration: Topical start_date: '2024-06-09' indication_for_use: Neuropathic pain drug_class: Anticonvulsant end_date: '2024-08-12' adverse_reactions: - symptom_name: Anaphylaxis onset_date: '2024-07-11' severity: Severe outcome: Unknown intervention_required: true - symptom_name: Nausea onset_date: '2024-07-11' severity: Severe outcome: Unknown intervention_required: false - symptom_name: Stevens-Johnson syndrome onset_date: '2024-07-11' severity: Life-threatening outcome: Fatal intervention_required: true intervention_details: Prescribed sing and advised boy. - symptom_name: Headache onset_date: '2024-07-11' severity: Severe outcome: Fatal intervention_required: true intervention_details: Prescribed box and advised inside. - symptom_name: Hepatotoxicity onset_date: '2024-07-11' severity: Moderate outcome: Recovered intervention_required: true intervention_details: Prescribed bar and advised again. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive rechallenge reporting_facility: Le and Sons Medical Center reporter_type: Nurse notes: Public manage prevent important claim. Dream people road Mr machine PM continue. Available too start worry.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-503 Date of Submission: 2025-03-25 This report was submitted by a Patient from Harris, Alvarado and Parsons Medical Center concerning patient ANON-PX-9869. The subject is a 38-year-old female with a significant medical history including coronary artery disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intravenous route at a dosage of 377mg, initiated on 2025-01-14 for Gastroesophageal reflux disease and discontinued on 2025-03-12; Sertraline (SSRI) administered via the Intravenous route at a dosage of 234mg, initiated on 2025-01-14 for Major depressive disorder and discontinued on 2025-03-12. On approximately 2025-03-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Anaphylaxis. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Many and including project trial. Nearly arm member student every social. Assume back significant book visit if if already.</data>	report_id: ADR-2025-503 report_date: '2025-03-25' patient_details: patient_id: ANON-PX-9869 gender: Female relevant_history: - coronary artery disease - seasonal allergies age_at_reaction: 38 suspected_drugs: - drug_name: Omeprazole dosage: 377mg route_of_administration: Intravenous start_date: '2025-01-14' indication_for_use: Gastroesophageal reflux disease end_date: '2025-03-12' - drug_name: Sertraline dosage: 234mg route_of_administration: Intravenous start_date: '2025-01-14' indication_for_use: Major depressive disorder drug_class: SSRI end_date: '2025-03-12' adverse_reactions: - symptom_name: Angioedema onset_date: '2025-03-05' severity: Mild outcome: Recovering intervention_required: true - symptom_name: Anaphylaxis onset_date: '2025-03-05' severity: Mild outcome: Fatal intervention_required: true causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Negative dechallenge naranjo_score: 4 reporting_facility: Harris, Alvarado and Parsons Medical Center reporter_type: Patient notes: Many and including project trial. Nearly arm member student every social. Assume back significant book visit if if already.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-739 Date of Submission: 2024-08-28 This report was submitted by a Pharmacist from Brandt PLC Medical Center concerning patient ANON-PX-1649. The subject is a 84-year-old male with a significant medical history including asthma, migraines, chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Intravenous route at a dosage of 332mg, initiated on 2024-06-19 for Type 2 diabetes and discontinued on 2024-08-18; Amoxicillin (Penicillin antibiotic) administered via the Subcutaneous route at a dosage of 359mg, initiated on 2024-06-19 for Bacterial infection and discontinued on 2024-08-18. On approximately 2024-07-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Anaphylaxis, Maculopapular Rash. The Pruritus was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2024-739 report_date: '2024-08-28' patient_details: patient_id: ANON-PX-1649 gender: Male relevant_history: - asthma - migraines - chronic kidney disease - anxiety age_at_reaction: 84 suspected_drugs: - drug_name: Metformin dosage: 332mg route_of_administration: Intravenous start_date: '2024-06-19' indication_for_use: Type 2 diabetes drug_class: Biguanide end_date: '2024-08-18' - drug_name: Amoxicillin dosage: 359mg route_of_administration: Subcutaneous start_date: '2024-06-19' indication_for_use: Bacterial infection drug_class: Penicillin antibiotic end_date: '2024-08-18' adverse_reactions: - symptom_name: Pruritus onset_date: '2024-07-29' severity: Severe outcome: Unknown intervention_required: false - symptom_name: Anaphylaxis onset_date: '2024-07-29' severity: Mild outcome: Recovered intervention_required: false - symptom_name: Maculopapular Rash onset_date: '2024-07-29' severity: Life-threatening outcome: Not Recovered intervention_required: false causality_assessment: assessment_conclusion: Highly Probable dechallenge_rechallenge: Positive dechallenge naranjo_score: 10 reporting_facility: Brandt PLC Medical Center reporter_type: Pharmacist
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-230 Date of Submission: 2024-10-12 This report was submitted by a Other Healthcare Professional from Hampton Inc Medical Center concerning patient ANON-PX-2219. The subject is a 77-year-old other with a significant medical history including anxiety, chronic kidney disease, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Metformin administered via the Subcutaneous route at a dosage of 434mg, initiated on 2024-07-14 for Type 2 diabetes with the course ongoing. On approximately 2024-07-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Nausea, Angioedema, Somnolence, Dizziness. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed knowledge and advised anything. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed country and advised too. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Travel ago team agent pressure beyond.</data>	report_id: ADR-2024-230 report_date: '2024-10-12' patient_details: patient_id: ANON-PX-2219 gender: Other relevant_history: - anxiety - chronic kidney disease - asthma age_at_reaction: 77 suspected_drugs: - drug_name: Metformin dosage: 434mg route_of_administration: Subcutaneous start_date: '2024-07-14' indication_for_use: Type 2 diabetes adverse_reactions: - symptom_name: Stevens-Johnson syndrome onset_date: '2024-07-21' severity: Moderate outcome: Not Recovered intervention_required: true intervention_details: Prescribed knowledge and advised anything. - symptom_name: Nausea onset_date: '2024-07-21' severity: Mild outcome: Fatal intervention_required: false - symptom_name: Angioedema onset_date: '2024-07-21' severity: Severe outcome: Recovered intervention_required: true - symptom_name: Somnolence onset_date: '2024-07-21' severity: Moderate outcome: Recovered intervention_required: false - symptom_name: Dizziness onset_date: '2024-07-21' severity: Life-threatening outcome: Recovered intervention_required: true intervention_details: Prescribed country and advised too. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Rechallenge not performed reporting_facility: Hampton Inc Medical Center reporter_type: Other Healthcare Professional notes: Travel ago team agent pressure beyond.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-477 Date of Submission: 2025-05-02 This report was submitted by a Other Healthcare Professional from Jensen Inc Medical Center concerning patient ANON-PX-7599. The subject is a 39-year-old female with a significant medical history including migraines, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Amoxicillin administered via the Subcutaneous route at a dosage of 261mg, initiated on 2025-02-20 for Bacterial infection and discontinued on 2025-04-06; Atorvastatin administered via the Intramuscular route at a dosage of 462mg, initiated on 2025-02-20 for Hypercholesterolemia and discontinued on 2025-04-06. On approximately 2025-03-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Somnolence. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed modern and advised throw. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2025-477 report_date: '2025-05-02' patient_details: patient_id: ANON-PX-7599 gender: Female relevant_history: - migraines - anxiety age_at_reaction: 39 suspected_drugs: - drug_name: Amoxicillin dosage: 261mg route_of_administration: Subcutaneous start_date: '2025-02-20' indication_for_use: Bacterial infection end_date: '2025-04-06' - drug_name: Atorvastatin dosage: 462mg route_of_administration: Intramuscular start_date: '2025-02-20' indication_for_use: Hypercholesterolemia end_date: '2025-04-06' adverse_reactions: - symptom_name: Headache onset_date: '2025-03-05' severity: Severe outcome: Fatal intervention_required: true intervention_details: Prescribed modern and advised throw. - symptom_name: Somnolence onset_date: '2025-03-05' severity: Life-threatening outcome: Recovering intervention_required: false causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Positive dechallenge naranjo_score: 3 reporting_facility: Jensen Inc Medical Center reporter_type: Other Healthcare Professional
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-416 Date of Submission: 2025-07-19 This report was submitted by a Pharmacist from Patel, Rose and Hall Medical Center concerning patient ANON-PX-4993. The subject is a 88-year-old male with a significant medical history including hypertension, atrial fibrillation, chronic kidney disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Warfarin administered via the Topical route at a dosage of 457mg, initiated on 2025-06-16 for Thromboembolism prevention with the course ongoing. On approximately 2025-06-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Dizziness, Diarrhea, Hepatotoxicity, Stevens-Johnson syndrome. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed significant and advised set. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed where and advised concern. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed money and advised list. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Thing song big high. Resource democratic happy prove. Success matter draw might.</data>	report_id: ADR-2025-416 report_date: '2025-07-19' patient_details: patient_id: ANON-PX-4993 gender: Male relevant_history: - hypertension - atrial fibrillation - chronic kidney disease - seasonal allergies age_at_reaction: 88 suspected_drugs: - drug_name: Warfarin dosage: 457mg route_of_administration: Topical start_date: '2025-06-16' indication_for_use: Thromboembolism prevention adverse_reactions: - symptom_name: Nausea onset_date: '2025-06-29' severity: Severe outcome: Fatal intervention_required: false - symptom_name: Dizziness onset_date: '2025-06-29' severity: Severe outcome: Not Recovered intervention_required: true intervention_details: Prescribed significant and advised set. - symptom_name: Diarrhea onset_date: '2025-06-29' severity: Life-threatening outcome: Recovered intervention_required: true intervention_details: Prescribed where and advised concern. - symptom_name: Hepatotoxicity onset_date: '2025-06-29' severity: Severe outcome: Recovered intervention_required: true intervention_details: Prescribed money and advised list. - symptom_name: Stevens-Johnson syndrome onset_date: '2025-06-29' severity: Severe outcome: Fatal intervention_required: false causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Negative dechallenge naranjo_score: 6 reporting_facility: Patel, Rose and Hall Medical Center reporter_type: Pharmacist notes: Thing song big high. Resource democratic happy prove. Success matter draw might.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-396 Date of Submission: 2025-04-05 This report was submitted by a Pharmacist from Wilson, Jones and Schaefer Medical Center concerning patient ANON-PX-2020. The subject is a 28-year-old other with a significant medical history including chronic kidney disease, atrial fibrillation, osteoarthritis, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Subcutaneous route at a dosage of 311mg, initiated on 2025-02-22 for Hypothyroidism and discontinued on 2025-03-31; Ibuprofen (NSAID) administered via the Intramuscular route at a dosage of 423mg, initiated on 2025-02-22 for Pain and inflammation and discontinued on 2025-03-31. On approximately 2025-03-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Hepatotoxicity, Maculopapular Rash, Diarrhea, Anaphylaxis. The Somnolence was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Affect remember ago question hair plan. Ever kitchen cut local determine fund.</data>	report_id: ADR-2025-396 report_date: '2025-04-05' patient_details: patient_id: ANON-PX-2020 gender: Other relevant_history: - chronic kidney disease - atrial fibrillation - osteoarthritis - hypertension age_at_reaction: 28 suspected_drugs: - drug_name: Levothyroxine dosage: 311mg route_of_administration: Subcutaneous start_date: '2025-02-22' indication_for_use: Hypothyroidism drug_class: Thyroid hormone end_date: '2025-03-31' - drug_name: Ibuprofen dosage: 423mg route_of_administration: Intramuscular start_date: '2025-02-22' indication_for_use: Pain and inflammation drug_class: NSAID end_date: '2025-03-31' adverse_reactions: - symptom_name: Somnolence onset_date: '2025-03-12' severity: Mild outcome: Unknown intervention_required: false - symptom_name: Hepatotoxicity onset_date: '2025-03-12' severity: Life-threatening outcome: Recovered intervention_required: false - symptom_name: Maculopapular Rash onset_date: '2025-03-12' severity: Moderate outcome: Unknown intervention_required: false - symptom_name: Diarrhea onset_date: '2025-03-12' severity: Life-threatening outcome: Not Recovered intervention_required: false - symptom_name: Anaphylaxis onset_date: '2025-03-12' severity: Severe outcome: Unknown intervention_required: false causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Not applicable naranjo_score: 4 reporting_facility: Wilson, Jones and Schaefer Medical Center reporter_type: Pharmacist notes: Affect remember ago question hair plan. Ever kitchen cut local determine fund.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-949 Date of Submission: 2025-01-15 This report was submitted by a Nurse from Grimes-Simpson Medical Center concerning patient ANON-PX-4802. The subject is an adult male with a significant medical history including migraines, osteoarthritis, type 2 diabetes, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Warfarin administered via the Subcutaneous route at a dosage of 81mg, initiated on 2024-10-25 for Thromboembolism prevention and discontinued on 2025-01-05; Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 491mg, initiated on 2024-10-25 for Neuropathic pain and discontinued on 2025-01-05. On approximately 2024-11-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Pruritus, Diarrhea, Nausea. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2025-949 report_date: '2025-01-15' patient_details: patient_id: ANON-PX-4802 gender: Male relevant_history: - migraines - osteoarthritis - type 2 diabetes - anxiety suspected_drugs: - drug_name: Warfarin dosage: 81mg route_of_administration: Subcutaneous start_date: '2024-10-25' indication_for_use: Thromboembolism prevention end_date: '2025-01-05' - drug_name: Gabapentin dosage: 491mg route_of_administration: Topical start_date: '2024-10-25' indication_for_use: Neuropathic pain drug_class: Anticonvulsant end_date: '2025-01-05' adverse_reactions: - symptom_name: Angioedema onset_date: '2024-11-09' severity: Moderate outcome: Not Recovered intervention_required: false - symptom_name: Pruritus onset_date: '2024-11-09' severity: Mild outcome: Recovering intervention_required: false - symptom_name: Diarrhea onset_date: '2024-11-09' severity: Mild outcome: Fatal intervention_required: false - symptom_name: Nausea onset_date: '2024-11-09' severity: Severe outcome: Recovered intervention_required: false causality_assessment: assessment_conclusion: Possible dechallenge_rechallenge: Positive dechallenge naranjo_score: 4 reporting_facility: Grimes-Simpson Medical Center reporter_type: Nurse
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2024-936 Date of Submission: 2024-10-31 This report was submitted by a Pharmacist from Day-Hill Medical Center concerning patient ANON-PX-3967. The subject is an adult other with a significant medical history including hypertension, osteoarthritis, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Intramuscular route at a dosage of 246mg, initiated on 2024-08-26 for Hypothyroidism with the course ongoing. On approximately 2024-10-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Anaphylaxis, Dizziness, Stevens-Johnson syndrome. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed store and advised work. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed star and advised arrive. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed go and advised seem. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed traditional and advised sister. The current patient status regarding this symptom is 'Not Recovered'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. Reporter's Narrative Summary: Star through tend. Prevent suffer character color parent. More chair join material fine mind purpose.</data>	report_id: ADR-2024-936 report_date: '2024-10-31' patient_details: patient_id: ANON-PX-3967 gender: Other relevant_history: - hypertension - osteoarthritis - atrial fibrillation suspected_drugs: - drug_name: Levothyroxine dosage: 246mg route_of_administration: Intramuscular start_date: '2024-08-26' indication_for_use: Hypothyroidism adverse_reactions: - symptom_name: Angioedema onset_date: '2024-10-24' severity: Life-threatening outcome: Unknown intervention_required: true intervention_details: Prescribed store and advised work. - symptom_name: Anaphylaxis onset_date: '2024-10-24' severity: Mild outcome: Fatal intervention_required: true intervention_details: Prescribed star and advised arrive. - symptom_name: Dizziness onset_date: '2024-10-24' severity: Life-threatening outcome: Recovered intervention_required: true intervention_details: Prescribed go and advised seem. - symptom_name: Stevens-Johnson syndrome onset_date: '2024-10-24' severity: Mild outcome: Not Recovered intervention_required: true intervention_details: Prescribed traditional and advised sister. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive dechallenge reporting_facility: Day-Hill Medical Center reporter_type: Pharmacist notes: Star through tend. Prevent suffer character color parent. More chair join material fine mind purpose.
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL Report Identifier: ADR-2025-390 Date of Submission: 2025-08-01 This report was submitted by a Pharmacist from Holmes, Rodriguez and Doyle Medical Center concerning patient ANON-PX-8248. The subject is a 35-year-old male with a significant medical history including hypertension, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Topical route at a dosage of 411mg, initiated on 2025-07-18 for Hypothyroidism with the course ongoing. On approximately 2025-07-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Somnolence, Nausea, Pruritus, Dizziness. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed west and advised road. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed response and advised behavior. The current patient status regarding this symptom is 'Fatal'. CAUSALITY ASSESSMENT: An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. </data>	report_id: ADR-2025-390 report_date: '2025-08-01' patient_details: patient_id: ANON-PX-8248 gender: Male relevant_history: - hypertension - seasonal allergies age_at_reaction: 35 suspected_drugs: - drug_name: Levothyroxine dosage: 411mg route_of_administration: Topical start_date: '2025-07-18' indication_for_use: Hypothyroidism adverse_reactions: - symptom_name: Headache onset_date: '2025-07-23' severity: Severe outcome: Fatal intervention_required: false - symptom_name: Somnolence onset_date: '2025-07-23' severity: Severe outcome: Unknown intervention_required: true intervention_details: Prescribed west and advised road. - symptom_name: Nausea onset_date: '2025-07-23' severity: Severe outcome: Unknown intervention_required: true - symptom_name: Pruritus onset_date: '2025-07-23' severity: Moderate outcome: Fatal intervention_required: true - symptom_name: Dizziness onset_date: '2025-07-23' severity: Life-threatening outcome: Fatal intervention_required: true intervention_details: Prescribed response and advised behavior. causality_assessment: assessment_conclusion: Probable dechallenge_rechallenge: Positive dechallenge reporting_facility: Holmes, Rodriguez and Doyle Medical Center reporter_type: Pharmacist